All articles tagged with #eps guidance
Pfizer has raised its 2025 EPS guidance to $2.90–$3.10 and aims for margin expansion through $7.7 billion in cost savings by 2027, with CEO Albert Bourla highlighting progress in R&D, portfolio expansion, and improved margins.
Philip Morris stock declined 2.82% in pre-market trading after reporting mixed Q2 2025 results, with adjusted EPS of $1.91 beating estimates but revenue of $10.1 billion missing expectations. The company raised its full-year EPS guidance to $7.43-$7.56, likely surpassing Wall Street estimates, and maintains a 'Strong Buy' analyst rating with a target price of $197.11, indicating a potential 9.21% upside.